## DXCM: DexCom, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.7% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($61.13)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. DXCM Deadline Approaching on December 26, 2025: Kessler**
- Source: GlobeNewswire | 20251205T110837 | Neutral | Relevance: 99%
- Kessler Topaz Meltzer & Check, LLP reminds investors of DexCom, Inc. (DXCM) about a class action lawsuit deadline on December 26, 2025. The lawsuit alleges that DexCom made material design changes to its continuous glucose monitoring systems (G6 and G7) without FDA authorization, rendering them less reliable and presenting health risks. Investors who purchased DexCom securities between January 8, 2024, and September 17, 2025, may be affected.

**2. DexCom, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before December 26, 2025 to Discuss Your Rights – DXCM**
- Source: KLAS 8 News Now | 20251204T211220 | Neutral | Relevance: 99%
-  DexCom, Inc. is facing a class action securities lawsuit alleging that the company made unauthorized design changes to its G6 and G7 glucose monitoring products, rendering them less reliable and potentially harmful. Investors who suffered losses between January 8, 2024, and September 17, 2025, are encouraged to contact Levi & Korsinsky, LLP by December 26, 2025, to discuss their rights and potentially serve as a lead plaintiff. The lawsuit claims that DexCom overstated the enhancements and reliability of the G7 device, while downplaying significant issues and health risks, leading to an increased risk of regulatory scrutiny and financial harm.

**3. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: WGN Radio 720 | 20251204T130853 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP is urging DexCom, Inc. (DXCM) investors who purchased securities between January 8, 2024, and September 17, 2025, to contact the firm regarding a securities class action. The lawsuit alleges that DexCom made false and misleading statements about its G6 and G7 continuous glucose monitoring systems, including unapproved design changes leading to inaccurate readings and patient injury risks. Investors have until December 26, 2025, to apply to be lead plaintiff.

**4. DexCom, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your Rights - DXCM**
- Source: PR Newswire | 20251204T140809 | Neutral | Relevance: 99%
-  The Gross Law Firm has issued a notice for shareholders of DexCom, Inc. (NASDAQ: DXCM) regarding a class action lawsuit. The lawsuit alleges that DexCom made unauthorized material design changes to its glucose monitoring products, the G6 and G7, which rendered them less reliable and posed health risks to users. Investors who purchased shares between January 8, 2024, and September 17, 2025, are encouraged to contact the firm before December 26, 2025, to discuss their rights and potential lead plaintiff appointment.

**5. DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class Action - Contact Lieff Cabraser**
- Source: FOX40 News | 20251204T130931 | Neutral | Relevance: 99%
-  Lieff Cabraser Heimann & Bernstein, LLP encourages investors of DexCom, Inc. (NASDAQ:DXCM) who purchased securities between January 8, 2024, and September 17, 2025, to contact them regarding a pending securities class action lawsuit. The lawsuit alleges that DexCom made false and misleading statements about design changes and issues with its G6 and G7 continuous glucose monitoring systems, which led to significant stock price declines. Investors have until December 26, 2025, to apply to be a lead plaintiff in the case.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $75 | $63 | +19% |
| 2025-11-25 | Evercore ISI Gr | $68 | $0 | 0% |
| 2025-11-10 | Morgan Stanley | $63 | $89 | -29% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | up | Overweight |
| 2025-11-25 | Evercore ISI Gr | init | In-Line |
| 2025-11-10 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.14M) |
| Sells | 3 ($0.45M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 61.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Tudor Investment Cor: 17.7% (+100.0%)
- Vanguard Group Inc: 12.7% (+2.4%)
- Blackrock Inc.: 10.0% (-0.5%)
- State Street Corpora: 4.3% (-0.0%)
- BAILLIE GIFFORD & CO: 4.1% (-4.9%)

### Key Risks

1. Long-term trend broken: trading 12.7% below SMA200.
2. Market regime shift could impact high-beta names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.85 indicates undervaluation relative to growth. Quality metrics strong (ROE 31%, margin 16%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $26.0B |
| Beta | 1.51 |
| 52W Range | $54.11 - $93.25 |
| Short Interest | 4.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.85 |
| Forward P/E | 26.3 |
| Current P/E | 31.7 |
| YoY Growth | 20.4% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at 1.7% (minimal 5-day change). Below STRENGTH zone by 1.3pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Outperforming sector by 4.0pp, stock-specific strength. Below SMA200 (0.87x), long-term trend not supportive. MACD histogram positive (0.94), confirming momentum. RSI neutral at 59.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.69% (CS: 70) | Neutral |
| RSI_14 | 59.3 | Neutral |
| MACD Histogram | 0.94 | Bullish |
| vs SMA20 | 1.077x | Above |
| vs SMA50 | 1.022x | Above |
| vs SMA200 | 0.873x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $65.49
- **Stop Loss:** $61.13 (6.7% risk)
- **Target:** $69.85 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 114
- **Position Value:** $7,465.86
- **Portfolio %:** 7.47%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite persisting. Mixed earnings signals with industrial weakness (John Deere) offset by consumer/tech strength, while institutional flows show selective positioning rather than broad risk-off. Fed meeting in 9 days provides near-term catalyst but current data suggests status quo maintenance.*

### Earnings

**Next:** 2026-02-12 (Est: $0.65)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.57 | $0.61 | +7.5% |
| 2025Q2 | $0.44 | $0.48 | +8.2% |
| 2025Q1 | $0.33 | $0.32 | -2.6% |
| 2024Q4 | $0.50 | $0.45 | -9.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*